Your browser is no longer supported. Please, upgrade your browser.
Settings
SNY Sanofi daily Stock Chart
SNY [NYSE]
Sanofi
Index- P/E24.29 EPS (ttm)2.03 Insider Own16.40% Shs Outstand2.45B Perf Week2.03%
Market Cap120.69B Forward P/E14.67 EPS next Y3.36 Insider Trans0.00% Shs Float2.29B Perf Month0.59%
Income5.23B PEG2.48 EPS next Q0.78 Inst Own10.60% Short Float0.18% Perf Quarter8.69%
Sales39.84B P/S3.03 EPS this Y1.40% Inst Trans-1.02% Short Ratio2.18 Perf Half Y24.88%
Book/sh25.33 P/B1.95 EPS next Y6.77% ROA- Target Price51.75 Perf Year25.96%
Cash/sh- P/C- EPS next 5Y9.80% ROE- 52W Range36.81 - 50.24 Perf YTD21.88%
Dividend1.64 P/FCF- EPS past 5Y-4.60% ROI6.20% 52W High-1.89% Beta0.88
Dividend %3.33% Quick Ratio- Sales past 5Y-0.20% Gross Margin69.10% 52W Low33.90% ATR0.61
Employees106859 Current Ratio- Sales Q/Q12.20% Oper. Margin21.20% RSI (14)57.10 Volatility1.18% 1.05%
OptionableYes Debt/Eq- EPS Q/Q31.70% Profit Margin27.60% Rel Volume0.32 Prev Close49.59
ShortableYes LT Debt/Eq- EarningsJul 28 BMO Payout38.30% Avg Volume1.89M Price49.29
Recom1.70 SMA201.20% SMA502.29% SMA20015.34% Volume612,325 Change-0.60%
May-11-17Downgrade Berenberg Buy → Hold
Apr-07-17Downgrade HSBC Securities Hold → Reduce
Apr-06-17Initiated Argus Buy $50
Mar-09-17Initiated Liberum Hold
Nov-07-16Initiated Goldman Neutral
Sep-23-16Initiated Piper Jaffray Neutral
Sep-15-16Resumed JP Morgan Underweight
Sep-13-16Upgrade Exane BNP Paribas Underperform → Neutral
Sep-08-16Upgrade Berenberg Hold → Buy
May-03-16Downgrade HSBC Securities Buy → Hold
Dec-10-15Downgrade Exane BNP Paribas Neutral → Underperform
Dec-01-15Downgrade Morgan Stanley Overweight → Equal-Weight
Nov-09-15Downgrade Bernstein Outperform → Mkt Perform
Oct-15-15Upgrade Morgan Stanley Equal-Weight → Overweight
Apr-22-15Upgrade Citigroup Sell → Neutral
Apr-15-15Initiated Societe Generale Buy
Aug-03-12Downgrade Standpoint Research Buy → Hold
Jan-11-11Downgrade Jefferies Buy → Hold
Nov-16-09Initiated Deutsche Securities Buy
Oct-14-09Upgrade UBS Sell → Neutral
Jun-27-17 09:51AM  Regeneron: The More the Merrier? Barrons.com
09:37AM  Sanofi/Regeneron's Kevzara Gets Marketing Approval in EU Zacks
09:22AM  Amgen Gets Positive CHMP Opinion for Mimpara Label Expansion Zacks
01:45AM  Sanofi Announces Licensing of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis (RA) in the European Union PR Newswire
01:02AM  Sanofi and Regeneron Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union GlobeNewswire
01:00AM  Regeneron and Sanofi Announce Approval of Kevzara® (sarilumab) to Treat Adult Patients with Moderately to Severely Active Rheumatoid Arthritis in the European Union PR Newswire
12:42AM  [$$] Third Point Move Could Lead to Nestlé-LOréal Decoupling The Wall Street Journal
Jun-26-17 12:25PM  [$$] How Third Point's Nestlé Move Could Affect L'Oréal The Wall Street Journal
06:11AM  Domino Effect: Nestle Sale of L'Oreal Could Trigger Sanofi Move Bloomberg
Jun-23-17 05:25PM  Good Companies From Warren Buffett's Portfolio GuruFocus.com
12:14PM  Why Gilead Sciences Is Nearing Yet Another Mind-Bending Breakout TheStreet.com
09:06AM  Vertex on the Street: Analysts Recommendations in June 2017 Market Realist
Jun-22-17 03:00PM  Drugmakers May Lose $390B In Sales Over 5 Years Investopedia
10:54AM  Shire (SHPG) Receives MAA Validation for Veyvondi by EMA Zacks
Jun-20-17 07:31PM  Why ImmunoGen, Inc. Jumped Higher Today Motley Fool
03:36PM  Eosinophilic Esophagitis: Major Market Opportunity for Dupixent? Market Realist
02:06PM  Dupixent May Prove Effective in Multiple Diseases Market Realist
02:03PM  Could Novartis' Drug Topple Regeneron's Blockbuster Eylea? Investor's Business Daily
11:24AM  Horizon Pharma Gets Health Canada Approval for Procysbi Zacks
09:07AM  Dupixent May Be a Major Growth Driver for Regeneron in 2017 Market Realist
08:39AM  4 Buy-Ranked Large Cap Pharma Stocks to Add to Your Portfolio Zacks
07:36AM  Regenerons Praluent May See Gradual Increase in 2017 Demand Market Realist
Jun-19-17 09:35AM  Sanofi: Should Value Investors Consider SNY Stock? Zacks
07:37AM  Regeneron Expected to Report Healthy Revenue Growth in 2017 Market Realist
06:00AM  Health Care Stocks Are Crushing the S&P 500 Investopedia
Jun-16-17 07:23AM  Sanofi chief says U.S. Supreme Court ruling on biologics has "immediate impact" Reuters
Jun-15-17 09:08AM  Pfizer (PFE) Buys Exclusive EU Rights to Anti-Fungal Drug Zacks
Jun-14-17 06:30PM  Start Your Morning With a Cup of Coffee and an Ounce of Dengue Prevention PR Newswire
07:34AM  Sanofi to invest further in biologics Reuters
06:00AM  10 High-Quality Foreign-Stock Bargains Morningstar
04:51AM  Sanofi to invest further in biologics Reuters
Jun-13-17 10:16AM  Seres Therapeutics' Stock Up as SER-109 Moves to Phase III Zacks
10:03AM  Intercept (ICPT) Releases Data from Phase II Flint Trial Zacks
08:15AM  Featured Company News - Data Indicates Sanofi's Soliqua(R) 100/33 Helps in Lowering Hba1c Levels in Type-2 Diabetes Patients Accesswire
Jun-12-17 04:32PM  Are Sanofi, Gilead In A Bidding War Over This Small-Cap Biotech? Investor's Business Daily
04:12PM  Is Regeneron, Sanofi's Eczema Drug Headed For Blockbuster Status? Investor's Business Daily
01:44PM  3 Large Cap Pharma Stocks to Buy Now Zacks
01:06PM  Tesaro Stock Jumps on Sanofi, Gilead Takeover Interest TheStreet.com
12:21PM  E3 2017: Video Games, Virtual Reality, Entertainment News Investor's Business Daily
08:49AM  Sanofi/Regeneron's Praluent Cuts Bad Cholesterol in Studies Zacks
08:40AM  Is the Options Market Predicting a Spike in Sanofi (SNY) Stock? Zacks
Jun-11-17 11:38AM  Sanofi-Regeneron's Praluent cuts cholesterol in Odyssey trials Reuters
11:03AM  Sanofi and Regeneron Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia GlobeNewswire
11:00AM  Regeneron and Sanofi Announce Positive Results from First Dedicated Studies Evaluating Praluent® (alirocumab) in Individuals with Diabetes and Hypercholesterolemia PR Newswire
Jun-10-17 01:01PM  New Analysis Shows Sanofi's Soliqua® 100/33 Lowered HbA1c by More Than 2 Percent in Patients with Screening Levels Greater than 9 Percent PR Newswire
01:01PM  In Senior Adults Treated with Basal Insulin, Switching to Sanofi's Toujeo® Halved Hypoglycemia Risk PR Newswire
Jun-09-17 06:26AM  Regeneron (REGN) Up 7.3% Since Earnings Report: Can It Continue? Zacks
Jun-08-17 08:20PM  It takes billions of dollars to bring a new drug to the market; here are some of the reasons why American City Business Journals
Jun-07-17 04:22PM  Will Regeneron's Cholesterol-Buster Get Booted In Amgen Battle? Investor's Business Daily
Jun-06-17 05:41PM  Regeneron, Sanofi urge court to reverse ban on cholesterol drug Reuters
03:03PM  Regeneron vs Amgen: Does The Patent Battle Even Matter? Barrons.com
08:40AM  Sanofi (SNY): Strong Industry, Solid Earnings Estimate Revisions Zacks
Jun-05-17 10:35AM  Regeneron Announces Positive Data on Carcinoma Candidate Zacks
Jun-04-17 10:00AM  Sanofi and Regeneron Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
10:00AM  Regeneron and Sanofi Present Positive Study Results for Investigational PD-1 Antibody REGN2810 at American Society of Clinical Oncology (ASCO) Annual Meeting PR Newswire
May-31-17 04:05PM  Big Pharma Diabetes Drugs Not So Sweet. What's in Store? Zacks
03:44PM  3 Top Dividend Stocks in Diabetes Treatment Motley Fool
10:08AM  5 Drug Stocks in Focus on World MS Day Zacks
09:15AM  How Regeneron Pharmaceuticals, Inc. Makes Most of Its Money Motley Fool
May-30-17 12:55PM  ImmunoGen grabs $30M in reworked cancer drug pact with Sanofi American City Business Journals
09:01AM  Sanofi (SNY) Stock Continues to Gain on Key Drug Approvals Zacks
07:37AM  Performance of Sanofi Pasteur in 1Q17 Market Realist
07:23AM  The 5 Best Dividend Stocks in Cholesterol Drugs Motley Fool
May-29-17 10:36AM  Sanofis Generics and Consumer Healthcare Business in 1Q17 Market Realist
09:06AM  Performance of Sanofis Established Prescription Products in 1Q17 Market Realist
07:37AM  Performance of Sanofis Diabetes and Cardiovascular Franchise in 1Q17 Market Realist
May-26-17 04:20PM  Are Regeneron, Sanofi Treading On Pfizer In Eczema? Investor's Business Daily
03:02PM  3 Top Dividend Stocks in Generic Drugs Motley Fool
11:33AM  Sony Patent Infringement Claim Results in Investigation of FujiFilm Imports TheStreet.com
10:37AM  Performance of Sanofi Genzyme in 1Q17 Market Realist
09:08AM  Sanofis Revenue Growth in 1Q17 Market Realist
08:08AM  Pharma Stock Roundup: Label Expansion for Merck Drug, Aerie Up On Eye Data Zacks
07:37AM  Changes in Sanofis Valuation after Its 1Q17 Earnings Market Realist
May-25-17 01:41PM  Symantec Fingers North Korea as Perpetrator Behind 'WannaCry' Ransomware Attacks TheStreet.com
07:43AM  Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline Zacks
May-24-17 09:06AM  Gardasil and Mercks Vaccines Business in 1Q17 Market Realist
May-23-17 04:25PM  Regeneron, Sanofi Undercut Amgen, AbbVie In Rheumatoid Arthritis Investor's Business Daily
03:08PM  Sanofi Genzyme takes on worlds top-selling drugs with new approval American City Business Journals
10:25AM  Sanofi/Regeneron's Kevzara Gets FDA Approval for Arthritis Zacks
May-22-17 06:35PM  Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval Reuters
06:05PM  Regeneron, Sanofi rheumatoid arthritis drug wins U.S. approval Reuters
05:47PM  Sanofi and Regeneron Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients PR Newswire
05:45PM  Regeneron and Sanofi Announce FDA Approval of Kevzara® (sarilumab) for the Treatment of Moderately to Severely Active Rheumatoid Arthritis in Adult Patients PR Newswire
04:38PM  Sanofi Wins Favorable CHMP Opinion for Biosimilar Humalog Zacks
02:08PM  Regeneron And Sanofi Have A Near-Term FDA Catalyst Benzinga
09:06AM  Merck vs. Sanofi: Which Stock is a Better Pick Post Q1 Earnings? Zacks
08:15AM  Blog Coverage: CHMP Okays French Pharma Major Sanofi's Insulin Lispro Biosimilar for Treatment of Diabetes Mellitus Accesswire
May-17-17 07:00AM  Bull of the Day: Regeneron (REGN) Zacks
May-16-17 05:42PM  [$$] Big pharma hopes rule change will ease China sales pain Financial Times
May-15-17 08:15AM  Post Earnings Coverage as Merck's EPS Surged 40%; Raised Outlook Accesswire
May-14-17 08:00PM  Henri Termeer, 'giant of biotech' and longtime CEO of Genzyme, dies at 71 American City Business Journals
May-12-17 01:26PM  Sanofi : SNY-US: Dividend Analysis : May 15th, 2017 (record date) : By the numbers : May 12, 2017 Capital Cube
12:04PM  Is Regeneron Pharmaceuticals Stock Still a Buy After Its Big Bounce? Motley Fool
May-11-17 03:49PM  There could a better way to protect against the flu, and it has implications for tackling HIV and the common cold Business Insider
08:30AM  Allegra® Allergy Gears Up for Bike to Work Day Across the U.S. PR Newswire
May-10-17 08:50PM  Another top executive at Sanofi Genzyme leaves company American City Business Journals
04:01PM  Mylan Q1 Revenue Falls Short Of Views As EpiPen Sales Decline Investor's Business Daily
12:20PM  Sanofi: Annual General Shareholders' Meeting of May 10, 2017 GlobeNewswire
11:38AM  Sanofi says has no "absolute need" to do acquisitions Reuters
May-09-17 10:33AM  Sanofi pegs U.S. drug price rises to below healthcare inflation Reuters
Sanofi researches, develops, manufactures, and markets therapeutic solutions. The company operates in two segments, Pharmaceuticals and Vaccines. It offers Cerezyme and Cerdelga for Gaucher disease, Myozyme and Lumizyme for Pompe disease, Fabrazyme for Fabry disease, and Aldurazyme for mucopolysaccharidosis Type 1; and Aubagio, an oral immunomodulatory and Lemtrada, a monoclonal antibody to treat multiple sclerosis. The company also provides Jevtana, a taxane derivative for prostate cancer; Taxotere, a taxoid for various cancers; Eloxatin, a platinum agent for colorectal cancer; Thymoglobulin, a immunosuppressive and immunomodulating agent; Mozobil, a hematopoietic stem cell mobilizer for hematologic malignancies; and Zaltrap, a protein for metastatic colorectal cancer. In addition, it offers Lantus, Apidra, and Insuman human insulins; Toujeo, an oral sulfonylurea; Lyxumia/Adlyxin, a GLP-1 receptor agonist; and Soliqua 100/33/Suliqua, an insulin glargine and lixisenatide combination to treat diabetes; and Praluent, a cholesterol-lowering drug and Multaq, an anti-arrhythmic drug to treat cardiovascular diseases. Further, the company provides Plavix, an anti-platelet agent for atherothrombotic conditions; Lovenox, a heparin for the prophylaxis and treatment of venous thromboembolism and acute coronary syndrome; Aprovel and CoAprovel anti-hypertensives; Renagel and Renvela oral phosphate binders for patients undergoing dialysis; Synvisc and Synvisc-One viscosupplements for patients with osteoarthritis; Stilnox for treatment of insomnia; and Allegra, an anti-histamine for the treatment of seasonal allergic rhinitis and uncomplicated hives. Additionally, it offers consumer health care products and generic medicines; and pediatric, influenza, adult and adolescent booster, meningitis, and travel and endemic vaccines. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was founded in 1973 and is headquartered in Paris, France.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sanofi10% OwnerJun 02Buy478.17136,05065,055,55823,641,744Jun 06 05:00 PM
Sanofi10% OwnerJan 11Buy369.7187,29832,274,87223,505,694Jan 13 04:15 PM